Medically reviewed by Qin Rao, MD Pancolitis, or extensive colitis, is a form of ulcerative colitis (UC) in which ...

MK-6194 is under clinical development by Merck and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 45% phase transition success rate ...

Lutikizumab is under clinical development by AbbVie and currently in Phase II for Crohn's Disease (Regional Enteritis).

Steqeyma is approved for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults ...

Nov. 19, 2024 — A study provides insights into the diversity of cancer-associated fibroblasts in white and black skin cancer and describes their different immunomodulatory roles in the tumor ...

Acne is the most common skin condition in the United States, affecting up to 50 million Americans annually. 1 There are different types of acne (blackheads, whiteheads, pimples, acne cysts or nodules) ...

Originally approved in 2009, Stelara patents began expiring in 2023, leading to an influx of recent biosimilars.

Teva and Sanofi report breakthrough results for duvakitug, showing strong efficacy in IBD. Learn how this TL1A drug could transform treatment options and reshape the market.

Teva and its partner Sanofi say 47.8% of patients with ulcerative colitis who received a high dose of their drug duvakitug experienced clinical remission, compared with 20.5% who received a placebo.